51784-03-3

Basic information

• Product Name: 2-PIPERIDIN-4-YL-BENZOOXAZOLE
• Synonyms: OTAVA-BB BB7020410137;CHEMBRDG-BB 4003380;BUTTPARK 90\08-60;AKOS BBS-00005830;2-PIPERIDIN-4-YL-BENZOOXAZOLE;2-PIPERIDIN-4-YL-1,3-BENZOXAZOLE;2-(4-PIPERIDINYL)-1,3-BENZOXAZOLE;2-piperidin-4-yl-1,3-benzoxazole(SALTDATA: FREE)
• CAS NO: 51784-03-3
• Molecular Formula: C₁₂H₁₄N₂O
• Molecular Weight: 202.25
• Mol File: 51784-03-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 114-116°C
• Boiling Point: 331.6 °C at 760 mmHg
• Flash Point: 154.3 °C
• Appearance: /
• Density: 1.143 g/cm³
• Vapor Pressure: 0.000154mmHg at 25°C
• Refractive Index: 1.582
• PKA: 9.87±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERIDIN-4-YL-BENZOOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERIDIN-4-YL-BENZOOXAZOLE(51784-03-3)
• EPA Substance Registry System: 2-PIPERIDIN-4-YL-BENZOOXAZOLE(51784-03-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 51784-03-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14N2O/c1-2-4-11-10(3-1)14-12(15-11)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2

Upstream product

• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 95-55-6 2-amino-phenol 
• 100-39-0 benzyl bromide 
• 2295-47-8 2-(pyridin-4-yl)benzoxazole 
• 498-94-2 isonipecotic acid 

Downstream Products

• 1026272-98-9 2-(1-{3-[2-(4-Fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-piperidin-4-yl)-benzooxazole 
• 1596340-61-2 2-(1-(5-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)pentyl)piperidin-4-yl)benzo[d]oxazole 
• 1596340-59-8 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole 
• 1596340-57-6 2-(1-(3-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)propyl)piperidin-4-yl)benzo[d]oxazole 
• 1159096-86-2 C₂₅H₂₂N₂O₂ 
• 199329-00-5 4-(Benzoxazol-2-yl)-1-benzyl-1,2,3,6-tetrahydropyridine hydrogen oxalate 
• 295789-95-6 C₂₂H₂₇N₃O₃S 

Relevant articles and documents

Chemical synthesis and molecular modeling of novel substituted N-1,3-benzoxazol-2yl benzene sulfonamides as inhibitors of inhA enzyme and Mycobacterium tuberculosis growth

Abstract: Tuberculosis (TB) is one of the major contagious diseases with high mortality which is caused by Mycobacterium tuberculosis (Mtb) pathogen. Due to the existing antibiotic resistance (MDR-TB) to tuberculosis, the demand for the development of new potential chemotherapy drugs is increasing. Herein, we report synthesis of two novel benzoxazole-based series, namely 2-phenyl benzoxazole sulfonamide and 2-piperidine-benzoxazole sulfonamides. These compounds were evaluated for their antimycobacterial activity against Mycobacterium tuberculosis H37Rv strain, using the microplate alamarBlue assay. Molecular docking studies were carried out to comprehend the binding mode of the compounds. It is evident from molecular docking studies and minimum inhibitory concentration assay (MIC) that 2-phenyl benzoxazole sulfonamide scaffold has a greater potential of antitubercular activity possibly by ENR inhibition (inhA inhibitors). In silico cytotoxicity studies using CLC-Pred tool database suggested that both the series were relatively safe. Graphic abstract: [Figure not available: see fulltext.].

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

Sulfonamide derivatives as 5-HT7 receptor antagonists

The invention relates to novel sulfonamide compounds having 5-HT7receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. wherein: Q is phenyl or thienyl; R1is halogen, hydroxy, C1-6alkyl, CF3, OCF3or C1-6alkoxy; m is 0, 1, 2 or 3; R2is C1-4alkyl; X is carbon or CH, is a single bond when X is nitrogen or CH or is a double bond when X is carbon, D is a single bond, C═O, O or CH2subject to the proviso that when X is nitrogen then D is not oxygen; P is a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R3is C1-6alkyl optionally substituted by NR4R5, aryl, arylC1-6alkyl, C1 6alkoxy, C1-6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR4R5, CONR4R5, NR4COR5, S(O)pNR4R5, CHO, OCF3, SCF3, CH2OR6, CO2R6or COR6where p is 0, 1 or 2 and R4, R5and R6are independently hydrogen, C1-6alkyl, aryl or arylC1-6alkyl; n is 0, 1, 2 or 3.